Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Find a Doctor

Reid W. Merryman, MD

Medical Oncology

 Make an Appointment
Watch Video

Reid W. Merryman, MD

Physician

  • Physician
  • Instructor in Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Autologous stem cell transplant
  • CAR T-cell therapy
  • Immunotherapies

Diseases Treated

  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemias
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin

Contact Information

  • Appointments617-632-6844
  • Office Phone Number617-632-3352
  • Fax617-632-4422
Make an Appointment

Bio

Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women's Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Care. He is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.

Board Certification:

  • Hematology/Oncology
  • Internal Medicine

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

  • Reid Merryman, MD
    News Releases
    12/7/2020

    Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma

    • Research
    • Lymphomas
    _
    News Releases
    12/1/2020

    Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting

    • Research
    • Myelodysplastic/Myeloproliferative Diseases
    • Multiple Myeloma
    • Lymphomas
    • Leukemias
    • Blood Cancer
    Reid Merryman, MD
    News Releases
    12/9/2019

    Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

    • Research
    • Lymphomas
    • Blood Cancer
    _
    News Releases
    11/26/2019

    Dana-Farber researchers to present more than 40 studies at 2019 ASH Annual Meeting

    • Research
    • Stem Cell/Bone Marrow Transplant
    • Blood Disorders
    • Waldenström’s Macroglobulinemia
    • Myelodysplastic/Myeloproliferative Diseases
    • Multiple Myeloma
    • Hodgkin lymphoma
    • Lymphomas
    • Chronic Myelogenous - CML
    • Acute Myeloid - AML
    • Acute Lymphoblastic - ALL
    • Leukemias
    • Blood Cancer
Top